Harbor Investment Advisory LLC Sells 1,985 Shares of Stryker Corporation $SYK

Harbor Investment Advisory LLC lessened its stake in shares of Stryker Corporation (NYSE:SYK) by 26.6% in the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 5,474 shares of the medical technology company’s stock after selling 1,985 shares during the period. Harbor Investment Advisory LLC’s holdings in Stryker were worth $1,799,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in SYK. Godfrey Financial Associates Inc. bought a new position in shares of Stryker during the 4th quarter valued at approximately $26,000. Sankala Group LLC bought a new stake in shares of Stryker in the 4th quarter worth approximately $26,000. United Financial Planning Group LLC purchased a new position in Stryker in the third quarter valued at approximately $27,000. Atlas Capital Advisors Inc. bought a new stake in shares of Stryker in the fourth quarter valued at $27,000. Finally, DJE Kapital AG bought a new stake in shares of Stryker in the fourth quarter valued at $28,000. Institutional investors own 77.09% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the company. Evercore set a $355.00 price target on Stryker in a research note on Friday, May 1st. Citigroup dropped their price objective on shares of Stryker from $420.00 to $385.00 and set a “buy” rating on the stock in a report on Tuesday, April 7th. JPMorgan Chase & Co. cut their target price on shares of Stryker from $445.00 to $400.00 and set an “overweight” rating for the company in a research report on Friday, May 1st. Needham & Company LLC reduced their target price on shares of Stryker from $454.00 to $418.00 and set a “buy” rating for the company in a research note on Friday, May 1st. Finally, Robert W. Baird set a $385.00 price target on shares of Stryker in a research report on Friday, May 1st. Sixteen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $395.33.

Insider Transactions at Stryker

In related news, Director Ronda E. Stryker sold 310,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the sale, the director owned 1,924,880 shares of the company’s stock, valued at approximately $601,005,282.40. This represents a 13.87% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP Robert S. Fletcher sold 4,544 shares of the stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the completion of the sale, the vice president owned 10,582 shares in the company, valued at $3,247,298.34. This represents a 30.04% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 323,264 shares of company stock valued at $100,659,489. 4.60% of the stock is currently owned by corporate insiders.

Stryker Price Performance

Shares of NYSE SYK opened at $314.81 on Wednesday. The stock has a market cap of $120.69 billion, a PE ratio of 36.44, a price-to-earnings-growth ratio of 2.12 and a beta of 0.78. Stryker Corporation has a fifty-two week low of $281.00 and a fifty-two week high of $404.87. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11. The stock has a fifty day moving average of $310.38 and a 200-day moving average of $339.43.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). Stryker had a return on equity of 23.42% and a net margin of 13.20%.The company had revenue of $6.02 billion for the quarter, compared to analysts’ expectations of $6.34 billion. During the same period last year, the company posted $2.84 EPS. The business’s revenue for the quarter was up 2.6% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Equities research analysts anticipate that Stryker Corporation will post 14.98 earnings per share for the current year.

Stryker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date of this dividend is Tuesday, June 30th. Stryker’s dividend payout ratio is presently 40.74%.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.